A Framework for Prioritizing Novel Agents in Malignant Peripheral Nerve Sheath Tumor Trials: A report from the Neurofibromatosis Clinical Trials Consortium
Clicks: 1
ID: 325573
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #84 of 125 articles by views in journal of neuro-oncology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 125 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Malignant peripheral nerve sheath tumors (MPNST) are soft tissue sarcomas, occurring either in people with Neurofibromatosis Type 1 (NF1) or sporadically, with a tendency for recurrence and distant metastases, and poor survival rates. The only proven curative treatment is complete oncologic resection, and there is currently no FDA-approved drug for the treatment of MPNST. Multiple clinical trials have failed to achieve improvement in survival and novel therapeutic approaches are urgently needed. To address this need, members of the MPNST Committee of the Congressionally Directed Medical Research Programs-supported Neurofibromatosis Clinical Trials Consortium convened to develop a framework to prioritize therapeutic agents with the highest potential for successful clinical development. We review the potential agents that may be prioritized and propose a methodology to evaluate available preclinical and clinical data. Increasing the availability and use of diverse preclinical models and defining the best preclinical endpoints prior to clinical translation can increase the success of clinical trials. Subsequently, utilizing a platform trial design can accelerate the clinical development process and facilitate patient accrual. It is imperative to foster collaborations with pharmaceutical companies and community partners. The integration of preclinical and clinical evaluation in an iterative and informative process can accelerate effective clinical development.
| Reference Key |
openalex_W7203793780
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Lindy Zhang, Vanessa Eulo, Srivandana Akshintala, Amy E. Armstrong, Andrea M. Gross, Laura J Klesse, Kathryn M. Lemberg, Varun Monga, Sameer Farouk Sait, Michael J Fisher, Brigitte C Widemann, Christine A Pratilas, Angela C. Hirbe, AeRang Kim |
| Journal | journal of neuro-oncology |
| Year | 2026 |
| DOI |
10.1093/neuonc/noag192
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.